Fyn kinase inhibition as a novel therapy for Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Nygaard, Haakon B ^a   Van Dyck, Christopher H ^a   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893832278     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt238     Document Type: Review

References (79)

1. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. J Lauren, DA Gimbel, HB Nygaard, JW Gilbert, SM Strittmatter, Nature 2009 457 1128 1132 10.1038/nature07761 19242475
2. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. JW Um, HB Nygaard, JK Heiss, MA Kostylev, M Stagi, A Vortmeyer, T Wisniewski, EC Gunther, SM Strittmatter, Nat Neurosci 2012 15 1227 1235 10.1038/nn.3178 22820466
3. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. JW Um, AC Kaufman, M Kostylev, JK Heiss, M Stagi, H Takahashi, ME Kerrisk, A Vortmeyer, T Wisniewski, AJ Koleske, EC Gunther, HB Nygaard, SM Strittmatter, Neuron 2013 79 887 902 10.1016/j.neuron.2013.06.036 24012003
4. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. M Larson, MA Sherman, F Amar, M Nuvolone, JA Schneider, DA Bennett, A Aguzzi, SE Lesne, J Neurosci 2012 32 16857a 16871a 10.1523/JNEUROSCI.1858-12.2012
5. Cellular functions regulated by Src family kinases. SM Thomas, JS Brugge, Annu Rev Cell Dev Biol 1997 13 513 609 10.1146/annurev.cellbio.13.1.513 9442882 (Pubitemid 28034534)
6. The hunting of the Src. GS Martin, Nat Rev Mol Cell Biol 2001 2 467 475 10.1038/35073094 11389470 (Pubitemid 33680585)
7. Structure and regulation of Src family kinases. TJ Boggon, MJ Eck, Oncogene 2004 23 7918 7927 10.1038/sj.onc.1208081 15489910 (Pubitemid 39468851)
8. Structures of Src-family tyrosine kinases. F Sicheri, J Kuriyan, Curr Opin Struct Biol 1997 7 777 785 10.1016/S0959-440X(97)80146-7 9434895 (Pubitemid 28025103)
9. Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes. D Jelic, B Mildner, S Kostrun, K Nujic, D Verbanac, O Culic, R Antolovic, W Brandt, J Med Chem 2007 50 1090 1100 10.1021/jm0607202 17315853 (Pubitemid 46496310)
10. Fyn, a potential target for Alzheimer's disease. K Yang, J Belrose, CH Trepanier, G Lei, MF Jackson, JF MacDonald, J Alzheimers Dis 2011 27 243 252 21799250
11. Identification of an alternatively spliced isoform of the fyn tyrosine kinase. JF Goldsmith, CG Hall, TP Atkinson, Biochem Biophys Res Commun 2002 298 501 504 10.1016/S0006-291X(02)02510-X 12408980 (Pubitemid 35333686)
12. Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. MP Cooke, RM Perlmutter, New Biol 1989 1 66 74 2488273
13. From axon-glial signalling to myelination: the integrating role of oligodendroglial Fyn kinase. EM Kramer-Albers, R White, Cell Mol Life Sci 2011 68 2003 2012 10.1007/s00018-010-0616-z 21207100
14. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. TH Nguyen, J Liu, PJ Lombroso, J Biol Chem 2002 277 24274 24279 10.1074/jbc.M111683200 11983687 (Pubitemid 34951945)
15. Fyn, a Src family tyrosine kinase. MD Resh, Int J Biochem Cell Biol 1998 30 1159 1162 10.1016/S1357-2725(98)00089-2 9839441 (Pubitemid 28515659)
16. Signal-processing machines at the postsynaptic density. MB Kennedy, Science 2000 290 750 754 10.1126/science.290.5492.750 11052931
17. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. T Nakazawa, S Komai, T Tezuka, C Hisatsune, H Umemori, K Semba, M Mishina, T Manabe, T Yamamoto, J Biol Chem 2001 276 693 699 11024032 (Pubitemid 32050862)
18. Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice. N Kojima, H Ishibashi, K Obata, ER Kandel, Learn Mem 1998 5 429 445 10489260 (Pubitemid 29108875)
19. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. SG Grant, TJ O'Dell, KA Karl, PL Stein, P Soriano, ER Kandel, Science 1992 258 1903 1910 10.1126/science.1361685 1361685 (Pubitemid 23026728)
20. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. K Prybylowski, K Chang, N Sans, L Kan, S Vicini, RJ Wenthold, Neuron 2005 47 845 857 10.1016/j.neuron.2005.08.016 16157279 (Pubitemid 41266951)
21. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. T Suzuki, K Okumura-Noji, Biochem Biophys Res Commun 1995 216 582 588 10.1006/bbrc.1995.2662 7488151
22. Long-term potentiation-a decade of progress? RC Malenka, RA Nicoll, Science 1999 285 1870 1874 10.1126/science.285.5435.1870 10489359 (Pubitemid 29444608)
23. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. PV Massey, BE Johnson, PR Moult, YP Auberson, MW Brown, E Molnar, GL Collingridge, ZI Bashir, J Neurosci 2004 24 7821 7828 10.1523/JNEUROSCI.1697-04.2004 15356193 (Pubitemid 39215685)
24. Activation of Fyn tyrosine kinase in the mouse dorsal hippocampus is essential for contextual fear conditioning. T Isosaka, K Hattori, S Kida, T Kohno, T Nakazawa, T Yamamoto, T Yagi, S Yuasa, Eur J Neurosci 2008 28 973 981 10.1111/j.1460-9568.2008.06405.x 18691323
25. Enhanced synaptic transmission and reduced threshold for LTP induction in fyn-transgenic mice. YF Lu, N Kojima, K Tomizawa, A Moriwaki, M Matsushita, K Obata, H Matsui, Eur J Neurosci 1999 11 75 82 10.1046/j.1460-9568.1999.00407.x 9987012 (Pubitemid 29012312)
26. Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. LW Babus, EM Little, KE Keenoy, SS Minami, E Chen, JM Song, J Caviness, SY Koo, DT Pak, GW Rebeck, RS Turner, HS Hoe, Brain Res 2011 1415 96 102 21872217
27. Initial events of myelination involve Fyn tyrosine kinase signalling. H Umemori, S Sato, T Yagi, S Aizawa, T Yamamoto, Nature 1994 367 572 576 10.1038/367572a0 7509042 (Pubitemid 24055518)
28. A unique role for Fyn in CNS myelination. BR Sperber, EA Boyle-Walsh, MJ Engleka, P Gadue, AC Peterson, PL Stein, SS Scherer, FA McMorris, J Neurosci 2001 21 2039 2047 11245687 (Pubitemid 32221386)
29. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. SK Shirazi, JG Wood, Neuroreport 1993 4 435 437 10.1097/00001756-199304000-00024 8388744 (Pubitemid 23116742)
30. Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium. YQ Luo, N Hirashima, YH Li, DL Alkon, T Sunderland, R Etcheberrigaray, B Wolozin, Brain Res 1995 681 65 74 10.1016/0006-8993(95)00282- U 7552293
31. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. ME Bamberger, ME Harris, DR McDonald, J Husemann, GE Landreth, J Neurosci 2003 23 2665 2674 12684452 (Pubitemid 36418601)
32. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. EA Grace, J Busciglio, J Neurosci 2003 23 493 502 12533609 (Pubitemid 36139548)
33. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? WL Klein, GA Krafft, CE Finch, Trends Neurosci 2001 24 219 224 10.1016/S0166-2236(00)01749-5 11250006 (Pubitemid 32204378)
34. Diffusible, nonfibrillar ligands derived from Aβ§ssub§1- 42§esub§ are potent central nervous system neurotoxins. MP Lambert, AK Barlow, BA Chromy, C Edwards, R Freed, M Liosatos, TE Morgan, I Rozovsky, B Trommer, KL Viola, P Wals, C Zhang, CE Finch, GA Krafft, WL Klein, Proc Natl Acad Sci U S A 1998 95 6448 6453 10.1073/pnas.95.11.6448 9600986 (Pubitemid 28249033)
35. Interaction between human prion protein and amyloid-beta (Aβ) oligomers: role of N-terminal residues. S Chen, SP Yadav, WK Surewicz, J Biol Chem 2010 285 26377 26383 10.1074/jbc.M110.145516 20576610
36. Prion protein and Aβ-related synaptic toxicity impairment. AM Calella, M Farinelli, M Nuvolone, O Mirante, R Moos, J Falsig, IM Mansuy, A Aguzzi, EMBO Mol Med 2010 2 306 314 10.1002/emmm.201000082 20665634
37. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. C Balducci, M Beeg, M Stravalaci, A Bastone, A Sclip, E Biasini, L Tapella, L Colombo, C Manzoni, T Borsello, R Chiesa, M Gobbi, M Salmona, G Forloni, Proc Natl Acad Sci U S A 2010 107 2295 2300 10.1073/pnas.0911829107 20133875
38. The prion protein as a receptor for amyloid-beta. HW Kessels, LN Nguyen, S Nabavi, R Malinow, Nature 2010 466 3 E4 discussion E4-E5 10.1038/nature09217 20703260
39. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. M Cisse, PE Sanchez, DH Kim, K Ho, GQ Yu, L Mucke, J Neurosci 2011 31 10427 10431 10.1523/JNEUROSCI.1459-11.2011 21775587
40. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. UK Resenberger, A Harmeier, AC Woerner, JL Goodman, V Muller, R Krishnan, RM Vabulas, HA Kretzschmar, S Lindquist, FU Hartl, G Multhaup, KF Winklhofer, J Tatzelt, EMBO J 2011 30 2057 2070 10.1038/emboj.2011.86 21441896
41. Amyloid-beta-induced synapse damage is mediated via cross-linkage of cellular prion proteins. C Bate, A Williams, J Biol Chem 2011 286 37955 37963 10.1074/jbc.M111.248724 21900234
42. Aβ inhibition of ionic conductance in mouse basal forebrain neurons is dependent upon the cellular prion protein PrPC. K Alier, L Ma, J Yang, D Westaway, JH Jhamandas, J Neurosci 2011 31 16292 16297 10.1523/JNEUROSCI.4367- 11.2011 22072680
43. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. E Chung, Y Ji, Y Sun, RJ Kascsak, RB Kascsak, PD Mehta, SM Strittmatter, T Wisniewski, BMC Neurosci 2010 11 130 10.1186/1471-2202-11-130 20946660
44. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. DA Gimbel, HB Nygaard, EE Coffey, EC Gunther, J Lauren, ZA Gimbel, SM Strittmatter, J Neurosci 2010 30 6367 6374 10.1523/JNEUROSCI.0395-10.2010 20445063
45. Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. W Kudo, HP Lee, WQ Zou, X Wang, G Perry, X Zhu, MA Smith, RB Petersen, HG Lee, Hum Mol Genet 2012 21 1138 1144 10.1093/hmg/ddr542 22100763
46. Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. H You, S Tsutsui, S Hameed, TJ Kannanayakal, L Chen, P Xia, JD Engbers, SA Lipton, PK Stys, GW Zamponi, Proc Natl Acad Sci U S A 2012 109 1737 1742 10.1073/pnas.1110789109 22307640
47. Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. WQ Zou, X Xiao, J Yuan, G Puoti, H Fujioka, X Wang, S Richardson, X Zhou, R Zou, S Li, X Zhu, PL McGeer, J McGeehan, G Kneale, DE Rincon-Limas, P Fernandez-Funez, HG Lee, MA Smith, RB Petersen, JP Guo, J Biol Chem 2011 286 15095 15105 10.1074/jbc.M110.199356 21393248
48. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. DB Freir, AJ Nicoll, I Klyubin, S Panico, JM McDonald, E Risse, EA Asante, MA Farrow, RB Sessions, HR Saibil, AR Clarke, MJ Rowan, DM Walsh, J Collinge, Nat Commun 2011 2 336 21654636
49. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. AE Barry, I Klyubin, JM McDonald, AJ Mably, MA Farrell, M Scott, DM Walsh, MJ Rowan, J Neurosci 2011 31 7259 7263 10.1523/JNEUROSCI.6500-10.2011 21593310
50. Src kinases: a hub for NMDA receptor regulation. MW Salter, LV Kalia, Nat Rev 2004 5 317 328 (Pubitemid 38478658)
51. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. PN Lacor, MC Buniel, PW Furlow, AS Clemente, PT Velasco, M Wood, KL Viola, WL Klein, J Neurosci 2007 27 796 807 10.1523/JNEUROSCI.3501-06.2007 17251419 (Pubitemid 46174498)
52. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. GM Shankar, S Li, TH Mehta, A Garcia-Munoz, NE Shepardson, I Smith, FM Brett, MA Farrell, MJ Rowan, CA Lemere, CM Regan, DM Walsh, BL Sabatini, DJ Selkoe, Nat Med 2008 14 837 842 10.1038/nm1782 18568035
53. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. GM Shankar, BL Bloodgood, M Townsend, DM Walsh, DJ Selkoe, BL Sabatini, J Neurosci 2007 27 2866 2875 10.1523/JNEUROSCI.4970-06.2007 17360908 (Pubitemid 46438992)
54. Alzheimer's disease is a synaptic failure. DJ Selkoe, Science 2002 298 789 791 10.1126/science.1074069 12399581 (Pubitemid 35231524)
55. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. ED Roberson, K Scearce-Levie, JJ Palop, F Yan, IH Cheng, T Wu, H Gerstein, GQ Yu, L Mucke, Science 2007 316 750 754 10.1126/science.1141736 17478722 (Pubitemid 46717684)
56. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. K Bhaskar, GA Hobbs, SH Yen, G Lee, Neuropathol Appl Neurobiol 2010 36 462 477 10.1111/j.1365-2990.2010.01103.x 20609109
57. Disease-related modifications in tau affect the interaction between Fyn and Tau. K Bhaskar, SH Yen, G Lee, J Biol Chem 2005 280 35119 35125 10.1074/jbc.M505895200 16115884 (Pubitemid 41532698)
58. Phosphorylation of tau by fyn: implications for Alzheimer's disease. G Lee, R Thangavel, VM Sharma, JM Litersky, K Bhaskar, SM Fang, LH Do, A Andreadis, G Van Hoesen, H Ksiezak-Reding, J Neurosci 2004 24 2304 2312 10.1523/JNEUROSCI.4162-03.2004 14999081 (Pubitemid 38314562)
59. Tau interacts with src-family non-receptor tyrosine kinases. G Lee, ST Newman, DL Gard, H Band, G Panchamoorthy, J Cell Sci 1998 111 3167 3177 9763511 (Pubitemid 28532427)
60. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. ED Roberson, B Halabisky, JW Yoo, J Yao, J Chin, F Yan, T Wu, P Hamto, N Devidze, GQ Yu, JJ Palop, JL Noebels, L Mucke, J Neurosci 2011 31 700 711 10.1523/JNEUROSCI.4152-10.2011 21228179
61. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. LM Ittner, YD Ke, F Delerue, M Bi, A Gladbach, J van Eersel, H Wolfing, BC Chieng, MJ Christie, IA Napier, A Eckert, M Staufenbiel, E Hardeman, J Götz, Cell 2010 142 387 397 10.1016/j.cell.2010.06.036 20655099
62. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. C Cruchaga, JS Kauwe, K Mayo, N Spiegel, S Bertelsen, P Nowotny, AR Shah, R Abraham, P Hollingworth, D Harold, MM Owen, J Williams, S Lovestone, ER Peskind, G Li, JB Leverenz, D Galasko, JC Morris, AM Fagan, DM Holtzman, AM Goate, Alzheimer's Disease Neuroimaging Initiative, PLoS Genet 2010 6 1001101 10.1371/journal.pgen.1001101 20862329
63. Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. LM Bekris, S Millard, F Lutz, G Li, DR Galasko, MR Farlow, JF Quinn, JA Kaye, JB Leverenz, DW Tsuang, CE Yu, ER Peskind, Am J Med Genet B Neuropsychiatr Genet 2012 159B 874 883 10.1002/ajmg.b.32094 22927204
64. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Chin, JJ Palop, GQ Yu, N Kojima, E Masliah, L Mucke, J Neurosci 2004 24 4692 4697 10.1523/JNEUROSCI.0277- 04.2004 15140940 (Pubitemid 38656624)
65. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Chin, JJ Palop, J Puolivali, C Massaro, N Bien-Ly, H Gerstein, K Scearce-Levie, E Masliah, L Mucke, J Neurosci 2005 25 9694 9703 10.1523/JNEUROSCI.2980-05.2005 16237174 (Pubitemid 41510910)
66. Fyn knock-down increases Abeta, decreases phospho-tau, and worsens spatial learning in 3xTg-AD mice. SS Minami, TG Clifford, HS Hoe, Y Matsuoka, GW Rebeck, Neurobiol Aging 2012 33 825 e15-e24 21782287
67. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Y Zhang, P Kurup, J Xu, N Carty, SM Fernandez, HB Nygaard, C Pittenger, P Greengard, SM Strittmatter, AC Nairn, PJ Lombroso, Proc Natl Acad Sci U S A 2010 107 19014 19019 10.1073/pnas.1013543107 20956308
68. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. G Dhawan, CK Combs, J Neuroinflamm 2012 9 117 10.1186/1742-2094-9-117
69. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. AS Baer, YA Syed, SU Kang, D Mitteregger, R Vig, C Ffrench-Constant, RJ Franklin, F Altmann, G Lubec, MR Kotter, Brain 2009 132 465 481 19208690
70. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. MW Appleby, JA Gross, MP Cooke, SD Levin, X Qian, RM Perlmutter, Cell 1992 70 751 763 10.1016/0092-8674(92)90309-Z 1516132
71. Impairment in the expression and activity of Fyn during differentiation of naive CD4§ssup§+§esup§ T cells into the Th2 subset. T Tamura, O Igarashi, A Hino, H Yamane, S Aizawa, T Kato, H Nariuchi, J Immunol 2001 167 1962 1969 11489976 (Pubitemid 32747501)
72. Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling. KB Reddy, DM Smith, EF Plow, J Cell Sci 2008 121 1641 1648 10.1242/jcs.014076 18430780 (Pubitemid 351911821)
73. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. F Piette, J Belmin, H Vincent, N Schmidt, S Pariel, M Verny, C Marquis, J Mely, L Hugonot-Diener, JP Kinet, P Dubreuil, A Moussy, O Hermine, Alzheimers Res Ther 2011 3 16 10.1186/alzrt75 21504563
74. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. LF Hennequin, J Allen, J Breed, J Curwen, M Fennell, TP Green, C Lambert-van der Brempt, R Morgentin, RA Norman, A Olivier, L Otterbein, PA Plé N Warin, G Costello, J Med Chem 2006 49 6465 6488 10.1021/jm060434q 17064066 (Pubitemid 44657442)
75. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. TC Gangadhar, JI Clark, T Karrison, TF Gajewski, Invest New Drugs 2013 31 769 773 10.1007/s10637-012-9897-4 23151808
76. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. A Gucalp, JA Sparano, J Caravelli, J Santamauro, S Patil, A Abbruzzi, C Pellegrino, J Bromberg, C Dang, M Theodoulou, J Massague, L Norton, C Hudis, TA Traina, Clin Breast Cancer 2011 11 306 311 10.1016/j.clbc.2011.03.021 21729667
77. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. HJ Mackay, HJ Au, E McWhirter, T Alcindor, A Jarvi, K MacAlpine, L Wang, JJ Wright, AM Oza, Invest New Drugs 2012 30 1158 1163 10.1007/s10637-011-9650-4 21400081
78. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). MG Fury, S Baxi, R Shen, KW Kelly, BL Lipson, D Carlson, H Stambuk, S Haque, DG Pfister, Anticancer Res 2011 31 249 253 21273606
79. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. DJ Renouf, MJ Moore, D Hedley, S Gill, D Jonker, E Chen, D Walde, R Goel, B Southwood, I Gauthier, W Walsh, L McIntosh, L Seymour, Invest New Drugs 2012 30 779 786 10.1007/s10637-010-9611-3 21170669